Thromb Haemost 1999; 81(06): 887-890
DOI: 10.1055/s-0037-1614593
Letters to the Editor
Schattauer GmbH

Long-term Management of Homozygous Protein C Deficiency: Replacement Therapy with Subcutaneous Purified Protein C Concentrate

C. Sanz-Rodriguez
1   From the Departments of Hematology and Madrid, Spain
,
J. J. Gil-Fernández
1   From the Departments of Hematology and Madrid, Spain
,
P. Zapater
2   Clinical Pharmacology, Hospital Universitario de la Princesa, Madrid, Spain
,
I. Pinilla
1   From the Departments of Hematology and Madrid, Spain
,
E. Granados
1   From the Departments of Hematology and Madrid, Spain
,
V. Gómez-G. de Soria
1   From the Departments of Hematology and Madrid, Spain
,
J. Cano
3   Department of Neonatology, Hospital Niño Jesús, Madrid, Spain
,
N. Sala
4   Medical and Molecular Genetics Center, Institut de Recerca Oncològica, Barcelona, Spain
,
J. M. Fernández-Rañada
1   From the Departments of Hematology and Madrid, Spain
,
N. Gómez Gómez
1   From the Departments of Hematology and Madrid, Spain
› Author Affiliations
Further Information

Publication History

Received 09 March 1998

Accepted after resubmission 05 March 1999

Publication Date:
09 December 2017 (online)

Summary

We present the case of a full-term newborn in whom purpura fulminans developed shortly after birth. A diagnosis of homozygous protein C deficiency was established based upon undetectable plasma protein C activity and antigenemia in the newborn infant, and was later confirmed by protein C gene analysis. Specific replacement therapy with intravenous protein C concentrate was started 9 days after birth. This rapidly led to the complete regression of cutaneous lesions and consumption coagulopathy. After stabilization, oral anticoagulation was initiated in association with prophylactic treatment with intravenous protein C concentrate. However, oral anticoagulation was finally abandoned as the patient presented several thrombotic and hemorrhagic episodes clearly related to difficulties with anticoagulation. Due to the hazards related to prolonged venous access, we are currently using subcutaneous infusion of protein C concentrate for the longterm management of this condition, with satisfactory results.

 
  • References

  • 1 Marlar RA, Montgomery RR, Broekmans AW. Report on the diagnosis and treatment of homozygous protein C deficiency. Thromb Haemost 1989; 61:: 529-31.
  • 2 Sills RH, Marlar RA, Montgomery RR, Deshpande GN, Humbert JR. Severe homozygous protein C deficiency. J Pediatr 1984; 105: 409-13.
  • 3 Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiency. Semin Thromb Haemostas 1990; 16: 299-309.
  • 4 Estellés A, García-Plaza I, Dasí A, Aznar J, Duart M, Sanz G, Pérez-Requejo JL, España F, Jiménez C, Abeledo G. Severe inherited “homozygous” protein C deficiency in a newborn infant. Thromb Haemost 1984; 52: 53-6.
  • 5 Peters C, Casella JF, Marlar RA, Montgomery RR, Zinkham WH. Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. Pediatrics 1988; 81: 272-6.
  • 6 Hartman KR, Manco-Johnson M, Rawlings JS, Bower DJ, Marlar RA. Homozygous protein C deficiency: early treatment with warfarin. Am J Pediatr Hematol Oncol 1989; 11: 395-401.
  • 7 Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, Rapaport I S. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984; 310: 559-62.
  • 8 Auletta MJ, Headington JT. Purpura fulminans: a cutaneous manifestation of severe protein C deficiency. Arch Dermatol 1988; 124: 1387-91.
  • 9 Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planché C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325: 1565-8.
  • 10 Müller D-F, Ehrenthal W, Hafner G, Schranz D. Purpura fulminans in homozygous protein C deficiency: monitoring of treatment with protein C concentrate. Eur J Pediatr 1996; 155: 20-5.
  • 11 Baliga V, Thwaites R, Tillyer ML, Minford A, Parapia L, Allgrove J. Homozygous protein C deficiency: management with protein C concentrate. Eur J Paediatr 1995; 154: 534-8.
  • 12 Dreyfus M, Masterson M, David M, Rivard GE, Müller FM, Kreuz W, Beeg H, Thomas H, Minford A, Allgrove J, Cohen H, Jesse H, Cristoph H, Bergman F, Mitchell NE, Vivian H, Haworth C, Nelson K, Schwarz HP. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemostas 1995; 21: 371-81.
  • 13 Goodwin TM, Gazit G, Gordon EM. Heterozygous protein C deficiency presenting as severe protein C deficiency and peripartum thrombosis: successful treatment with protein C concentrate. Obstet Gynecol 1995; 86: 662-4.
  • 14 Reitsma PH, Bernardi F, Doig RG, Gandrille S, Greengard JS, Ireland H, Krawczak M, Lind B, Long GL, Poort SR, Saito H, Sala N, Witt I, Cooper DN. Protein C deficiency: a database of mutations, 1995 update. Thromb Haemost 1995; 73: 876-89.
  • 15 Grandille S, Aiach M. and the French INSERM network on molecular abnormalities responsible for protein C and protein S deficiencies. Identification of mutations in 90 of 121 consecutive symptomatic French patients with type I protein C deficiency. Blood 1995; 86:: 2598-605.
  • 16 Millar DS, Wacey AI, Voke J, Kakkar VV, Cooper DN. A novel point mutation (Val297-Met) in the serine proteinase domain of protein C in a patient with venous and arterial thromboembolic disease. Blood Coagul Fibrinolysis 1993; 4: 631-3.
  • 17 Monagle P, Andrew M, Halton J, Marlar R, Jardine L, Vegh P, Johnston M, Webber C, Massicotte MP. Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular weight heparin. Thromb Haemost 1998; 79: 756-61.
  • 18 Minford AMB, Parapia LA, Stainforth C, Lee D. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J Haematol 1996; 93: 215-6.